Young head and neck cancer patients are at increased risk of developing oral mucositis and trismus

Objectives To evaluate cancer treatment–related toxicities in young head and neck cancer (HNC) patients. Material and methods A total of 44 patients were included in the present retrospective cohort study, which was designed to access oral toxicities of cancer treatment in young ( 58 years of age, G...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2020-09, Vol.28 (9), p.4345-4352
Main Authors: Morais-Faria, Karina, Palmier, Natalia Rangel, de Lima Correia, Jaqueline, de Castro Júnior, Gilberto, Dias, Reinaldo Brito, da Graça Pinto, Henrique, Lopes, Marcio Ajudarte, Ribeiro, Ana Carolina Prado, Brandão, Thaís Bianca, Santos-Silva, Alan Roger
Format: Article
Language:English
Subjects:
Cancer
Cancer patients
Cancer therapies
Deglutition disorders
Dysphagia
Head & neck cancer
Head and neck cancer
Medical colleges
Medicine
Medicine & Public Health
Mucositis
Nursing
Nursing Research
Oncology
Oncology, Experimental
Original Article
Pain Medicine
Palliative care
Radiation therapy
Rehabilitation Medicine
Stomatitis
Taste disorders
World health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To evaluate cancer treatment–related toxicities in young head and neck cancer (HNC) patients. Material and methods A total of 44 patients were included in the present retrospective cohort study, which was designed to access oral toxicities of cancer treatment in young ( 58 years of age, Group II, n  = 22) HNC patients with similar tumor stage and treatment protocols. Oral mucositis (OM), xerostomia, dysphagia, dysgeusia, trismus, and radiodermatitis were assessed during days 7th, 21st, and 35th of head and neck radiotherapy (HNRT) according to previously validated scales (World Health Organization criteria and the National Cancer Institute and Common Terminology Criteria for Adverse Events version 4.0). Results Patients from both groups showed high incidence and severity of oral toxicities by the end of the HNRT with OM (81.9% (Group I); 63.6% (Group II)) and xerostomia (72.6% (Group I); 77.2% (Group II)) being the most prevalent toxicities. No differences regarding xerostomia, dysphagia, dysgeusia, and radiodermatitis incidences or severity could be observed between groups. However, higher incidences and severity of OM at 21st and 35th fractions (odds ratio = 2.22 and 5.71, respectively) and trismus at 21st and 35th fractions (odds ratio = 6.17 and 14.5, respectively) were observed throughout the treatment in young patients when compared to older patients ( p  
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-019-05241-x